GlassScriptPhysician profile
Beth L Buchanan
NPI 1679597165
$8,642.12
in general payments reported to CMS, 2019-2025
51 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $691 · 2021: $1,222 · 2022: $921 · 2023: $1,030 · 2024: $1,590 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,147.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,038.91 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $752.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $727.52 | 2019-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.91 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $523.00 | 2019-2025 | Bevespi Aerosphere, Farxiga |
| Lilly USA, LLC | $478.71 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $471.90 | 2019-2024 | Otezla, Repatha |
| Supernus Pharmaceuticals, INC. | $323.56 | 2024 | Qelbree |
| Pfizer INC. | $307.93 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $302.94 | 2019-2021 | |
| Axsome Therapeutics, INC. | $276.74 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $220.60 | 2023-2025 | Veozah |
| Allergan, INC. | $182.91 | 2019-2020 | |
| Madrigal Pharmaceuticals | $182.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Vanda Pharmaceuticals INC. | $178.38 | 2019-2023 | Fanapt, Hetlioz |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.